The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Provider messaging for precision treatment (ProMPT): A notification pilot study to inform actionable genomic findings.
 
Neha M. Jain
No Relationships to Disclose
 
Curtis Schunk
No Relationships to Disclose
 
Joseph Abrams
No Relationships to Disclose
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Consulting or Advisory Role - Flatiron Health
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology
Other Relationship - Sarah Cannon Research Institute (Inst)
 
Garrett Young
No Relationships to Disclose
 
Davey B. Daniel
Employment - OneOncology
Leadership - OneOncology
Speakers' Bureau - HMP; IDEOlogy Health
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EQRx (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Merus NV (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
 
Thomas Stricker
No Relationships to Disclose